Eicosapentaenoic acid (EPA, an omega-3 fatty acid from fish oils) for the treatment of cancer cachexia
Dewey A, Baughan C, Dean T, Higgins B, Johnson I
The Cochrane database of systematic reviews · 98 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Metaanálisis (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2007-01-24 · Cochrane Database Syst Rev · vol. 2017 · número 12 · pág. CD004597
- Editorial
- Elsevier BV
- Citado
- 257 citas · más que el 98% de estudios similares · 9.1× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 92 trabajos
- Acceso
- Lectura gratuita
- Áreas de investigación
- Nutrition and Health in Aging · Clinical Nutrition and Gastroenterology · Fatty Acid Research and Health
- Palabras clave
- eicosapentaenoic acid, omega-3 fatty acids, fish oil, cancer cachexia, weight loss, advanced cancer, nutritional status, quality of life, adverse events, protein-energy supplementation, megestrol acetate, appetite stimulants, dose comparison
- MeSH
- humans, neoplasms, cachexia, eicosapentaenoic acid, nutritional status, randomized controlled trials as topic
5 autores
- Ann Dewey🇬🇧University of Portsmouth
- Chris Baughan🇬🇧Royal South Hants Hospital
- Taraneh Dean🇬🇧University of Portsmouth
- Bernie Higgins🇬🇧University of Portsmouth
- Ian Johnson🇬🇧Isle of Wight NHS Trust; Mountbatten Isle of Wight
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Cancer cachexia is a distressing weight loss syndrome commonly seen in advanced cancer patients. It is associated with reduced quality of life and shorter survival time. Eicosapentaenoic acid (EPA) is a long chain polyunsaturated fatty acid found naturally in some fish which has been used to decrease weight loss, promote weight gain and increase survival times in patients affected with cancer cachexia.
Objectives
To evaluate the effectiveness and safety of EPA in relieving symptoms associated with the cachexia syndrome in patients with advanced cancer.
Search strategy
Studies were sought through an extensive search of a range of electronic databases. Hand searching was conducted on selected journals and reference lists as well as contact made with investigators, manufacturers and experts. The most recent electronic search was conducted in February 2005.
Selection criteria
Studies were included in the review if they assessed oral EPA compared with placebo or control in randomised controlled trials of patients with advanced cancer and either a clinical diagnosis of cachexia or self-reported weight loss of 5% or more.
Data collection and analysis
Both methodological quality evaluation of potential trials and data extraction were conducted by two independent review authors.
Main results
Five trials (involving 587 patients) met the inclusion criteria. Three trials compared EPA at different doses with placebo with two outcomes, nutritional status and adverse events comparable across two of the three included trials. In addition, two trials compared different doses of EPA with an active matched control. It was possible to compare the outcomes of weight, quality of life and adverse events across these two trials. There were insufficient data to define the optimal dose of EPA.
Authors' conclusions
There were insufficient data to establish whether oral EPA was better than placebo. Comparisons of EPA combined with a protein energy supplementation versus a protein energy supplementation (without EPA) in the presence of an appetite stimulant (Megestrol Acetate) provided no evidence that EPA improves symptoms associated with the cachexia syndrome often seen in patients with advanced cancer.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.